Advancing Research

Defining Parkinson’s Disease for the Next Generation of Therapies

Group of researchers in the lab talking

As Parkinson’s research advances, experts are discussing how to biologically define and possibly classify Parkinson’s disease.                                   

Right now, a discussion is gaining momentum among scientists researching Parkinson’s disease (PD) to use the latest advances in research to define Parkinson’s for the first time, based upon its biological signature. But why? And more importantly, what does this mean for those living with PD right now and the 90,000 people diagnosed every year?

Currently, diagnosing Parkinson’s is a mix of art and science. A PD diagnosis is made when a doctor weighs the evidence contained in a combination of symptoms (clinical hallmarks), response to dopamine therapy and use of in-office exams. Sometimes, brain imaging or a skin biopsy can be used to help support the diagnosis. Ultimately, there is no single test that can unequivocally confirm a person has Parkinson’s and no test to track disease progression.

Why Scientists Believe We Need to Define Parkinson’s

Parkinson’s research is advancing. We are getting closer to being able to use a biomarker to diagnose Parkinson’s. For example, high blood pressure is a biomarker for hypertension and blood glucose levels are biomarkers for diabetes. For PD, reliable biomarkers could one day potentially lead to an earlier PD diagnosis and help researchers design and test therapies that might slow or stop the disease.

For PD, the protein alpha-synuclein can act as a biomarker. Years of research show that this protein is involved in most but not all PD cases. While the alpha-synuclein protein has a useful role in the body, in PD, it becomes misfolded and damaged. This misfolding, much like a crumpled piece of paper, is associated with the damage of brain cells and the formation of alpha-synuclein clumps called Lewy bodies. These protein depositions pathologically define PD and the related disease, Lewy Body Disease or Dementia with Lewy Bodies. 

We know from pivotal research, some of which was funded by the Parkinson’s Foundation and published in 2008, that misfolded alpha-synuclein can spread in the brain. The alpha-synuclein then acts as a “seed,” causing normal alpha-synuclein to form new clumps that change how brain cells work.

Recent advancements have opened the door for scientists to find misfolded alpha-synuclein in cerebrospinal fluid (CSF) of people with PD. This method for detecting abnormal alpha-synuclein is called alpha-synuclein seed amplification assay (SAA). In 2023, the accuracy of this approach was published. Recently in Nature, researchers from Japan published a blood-based approach to measure alpha synuclein.

Scientists believe the synuclein seed amplification assay could be an effective way to identify Parkinson’s in its “preclinical” stage, years before symptoms appear. However, the assay has its limitations. The testing method is not yet widely standardized and not all scientists have achieved the same results. The fluid required for the testing uses a spinal tap, which is a procedure that removes a small amount of cerebrospinal fluid and is not easily collected. The hope is that more serum and blood-based approaches will replace spinal fluid.

Also, the SAA assay test only confirms the presence of misfolded alpha-synuclein — it does not pick up all cases of Parkinson’s, especially cases of the LRRK2 genetic variant. Results cannot help scientists or doctors track disease progression, nor can it determine if someone who has misfolded alpha-synuclein — but no PD symptoms — will develop PD. Nevertheless, scientists — including those funded by the Parkinson’s Foundation — are working to overcome these limitations with the goal of re-engineering the SAA biomarker test to use a blood draw instead of CSF.

Scientists believe that using biomarkers to biologically define Parkinson’s can help identify early PD with more certainty and help to advance clinical trials. For now, alpha-synuclein is the first validated biomarker to be used in early clinical research. Researchers are already working on finding other PD biomarkers (through an MRI, skin biopsy and others) that can be used to diagnose PD and monitor its progression.

What’s in a name?

With the advancements being made in PD biomarkers, researchers are beginning to think about a new way of describing or “classifying” PD. This would provide a standardized way for researchers, doctors and epidemiologists (those who study disease) to describe PD and its various stages. This is in contrast with how we study PD right now, as Parkinson’s does not have a singular disease classification.

Because Parkinson’s is tied to the abnormal clumping of alpha-synuclein in the brain, some propose reframing “Parkinson’s disease” into a larger disease category. Two new approaches have recently been proposed:

Neuronal Synuclein Disease graphic

1.  Neuronal Synuclein Disease

The first presumes that alpha-synuclein is an effective, and potentially the only, biomarker to define diseases where alpha-synuclein plays a role, such as Parkinson’s and Lewy Body Disease (LBD). Researchers propose to use “Neuronal synuclein disease” as an umbrella term to describe PD and its alpha-synuclein related diseases as part of a proposed disease staging system (Simuni et al., 2024). This classification requires use of cerebrospinal fluid (CSF) and DaT brain scanning.

SynNeurGe graphic

2.  SynNeurGe

The second approach to classifying PD also relies on using alpha-synuclein as a biomarker but incorporates other disease features in classifying the disease (Höglinger et al., 2024). Here, researchers also use brain imaging and genetic status to define what is PD and what is not. The researchers do not propose changing the name of Parkinson’s disease but add the classification scheme, called “SynNeurGe” (pronounced synergy) alongside it.

Importantly, these two proposed approaches for defining PD lay important groundwork but also “underscores substantial knowledge gaps that deserve further study,” (Darweesh et al., 2024).

What This Means for The PD Community Right Now

The future of PD research lies in being able to define the disease based on a biological basis, which marks the beginning of more efficient ways to define, diagnose and treat PD. However, the work towards disease classification or a biological definition of PD will take time. Right now, these discussions do not impact how Parkinson’s is currently diagnosed or treated.

As researchers debate the merits of each approach (or even continue to propose new ones), it will take time to reach a consensus and to implement any changes to how PD is classified. If a new classification scheme is implemented, the likely first impact will be how clinical trials are conducted. Researchers may choose to fill research studies with participants who have received a diagnosis via the biomarker test, as they may respond better to certain drug treatments.

“Tying Parkinson’s disease to a new classification or definition is a new, evolving approach that will take time to first develop in research and then move into general use in the clinic. There will be ups and downs along the way, but with feedback from the community and continued advances in research the overall result will hopefully mean better care for people living with PD,” said James Beck, PhD, Parkinson’s Foundation Chief Scientific Officer.

In the meantime, it remains imperative that people who suspect they have Parkinson’s should be aware of the early signs and speak to their doctor. An early diagnosis will always remain the best course of treatment to maintain a high quality of life.

As research advances towards precision medicine, genetic testing is an important way researchers can help advance the field towards better treatments and diagnosis. Studies like PD GENEration: Mapping the Future of Parkinson's Disease are empowering people with Parkinson’s with their genetic status at no cost. These results can be shared with their doctor to guide treatment.

Here For the Parkinson’s Community

As this process unfolds, the Parkinson’s Foundation will continue to support innovative scientific research that improves life for people with PD and report any new information to our community. The Foundation continues to serve as a trusted ally to the Parkinson’s community, providing information that can help people navigate every stage of the disease.

Learn More

Learn more about advances in research by visiting the below Parkinson’s Foundation resources or by calling our free Helpline at 1-800-4PD-INFO (473-4636) for answers to your Parkinson’s questions.

Educational Events

Parkinsonisms

Virtual ( Zoom )
1:00 pm to 2:00 pm EST
Free
Husband and wife lookin at a tablet while on their porch

Wellness Wednesday

Parkinsonism is a term used to describe a collection of movement symptoms associated with several conditions including Parkinson’s disease. Learn about the types of Parkinsonisms and how they are diagnosed and treated.

Speaker

Jerome Lisk, MD, FAAN
Fellowship Trained in Movement Disorders 
Board Certified National Board of Physicians and Surgeons; Board Certified American Board of Psychiatry and Neurology
Clinical Assistant Professor at The University of North Texas Health Science Center at Fort Worth
Board of Directors, Texas Health Services Authority
MD Neurology Director of Movement Disorders Denton/Flower Mound, TX.

There is no charge to attend, but registration is required.

PD Health @ Home is presented by the Light of Day Foundation, whose generosity has made this programming possible.

Light of Day, Fighting Parkinson's, ALS, and PSP logo

This is a virtual program, taking place live, using the online Zoom platform. Instructions on joining the webinar are provided after registering.

Upcoming Events

Videos & Webinars

Expert Briefing: Research Update: Working to Halt PD

April 10, 2024

There is still a lot we don’t know about Parkinson’s disease (PD), and through research, efforts are being made to close the gaps in our knowledge and understanding.  In addition to the development of new therapies for symptom management, research also seeks to find ways to stop progression and ultimately end PD.  During this Expert Briefing, we will learn about current research that is taking various approaches to develop a treatment that may significantly slow PD’s progression.

Download Slides

Presenter

Lorraine Kalia, MD, PhD, FRCPC, Associate Professor
Division of Neurology, Department of Medicine at the University of Toronto
Toronto Western Research Institute
Tanz Centre for Research in Neurodegenerative Disease 

Videos & Webinars

Work It Out: Managing Parkinson’s in the Workplace

Being diagnosed with Parkinson’s disease (PD) can significantly disrupt every aspect of one's life, particularly when diagnosis occurs during prime working years. Remaining in or returning to employment, in particular, can cause anxiety. Regardless for the reasons for wanting to work, people with PD should be equipped with the knowledge and resources to make informed decisions.

Videos & Webinars

Los ejercicios recomendados para el Parkinson

No importa en qué punto se encuentre en su recorrido por la enfermedad de Parkinson, el movimiento habitual es una buena medicina. Los estudios demuestran que la incorporación de una rutina de ejercicio es esencial para el manejo de los síntomas de la enfermedad de Parkinson.

Fundraising Events

Community Walk Circleville

9:00 am to 12:00 pm CDT
FREE
Group of people going through the finish line at a Moving Day Walk

Get out and move with your community! Every dollar raised supports the Parkinson’s Foundation mission to make life better for people affected by Parkinson’s disease (PD). At Moving Day Community Walks across the country, we’re fighting Parkinson’s and celebrating movement — proven to help manage Parkinson’s symptoms — and we’re doing it together. The Moving Day Community Walk Program is a complement to the Parkinson’s Foundation Moving Day, A Walk for Parkinson’s. These walks are family-friendly and help the Foundation make life better for people with PD.

The Community Walk program offers volunteers an opportunity to organize a walk in their own community that does not have a Moving Day event. The program leverages the personal experiences and community leadership of passionate volunteers to promote Parkinson’s awareness and raise funds for the Parkinson’s Foundation.

Learn more about bringing an event to your area

Upcoming Events

Raise Awareness

Breaking Boundaries in Parkinson's Care: The Vision of Ruth Hagestuen

Ruth Hagestuen on vacation with two friends

Since every person has a unique Parkinson’s disease (PD) experience, building a diverse team of health experts allows them to manage their PD symptoms and progression — and maximize quality of life. No one understood this concept better than Ruth Hagestuen RN, MA, the founder of the Parkinson’s Foundation Team Training program, an interactive program designed to train healthcare teams in PD care.

Ruth passed away on February 23, 2024. This article is dedicated to Ruth and how she shaped Parkinson’s care, ultimately evolving how the Parkinson’s Foundation works to bring access to care to more people with Parkinson’s.

Ruth Hagestuen at ATTP Faculty Training in 2017

In a 2018 podcast episode, Ruth spoke about the Team Training program and its design. “The reason we decided to launch this program is that people with Parkinson’s were going for care and were not able to find professionals that knew PD well enough to give state-of-the-art care,” Ruth said. “We want every person that goes to the program to understand the best we know to date about Parkinson’s.”  

In 2000, Ruth joined the Parkinson’s Foundation as Vice President and Program Director, where she launched the Team Training program in 2003. She worked with affiliates nationally and internationally to develop strategies to better meet the needs of the PD community through research, education, care and outreach. 

2023 marked 20 years for the Parkinson’s Foundation Team Training program. Since inception, more than 2,900 health care professionals have graduated from the program, which has been hosted in cities across the U.S. and offered virtually.

Ruth Hagestuen at CPP in 2007

Ruth’s dream to train professionals continues to reach further, as Team Training alumni collectively treat nearly 200,000 people with Parkinson’s across the country each year.

Her legacy continues to impact people living with PD and the healthcare professionals who complete Team Training — including neurologists, nurses, social workers, rehab therapists and others.

“Ruth was a visionary in the Parkinson’s disease space. For decades, as a nurse she personally brought comfort and care to thousands of people living with the disease during her career, she ran one of the early leading PD centers in the U.S., and through Team Training, she helped train thousands of healthcare professionals,” said Eli Pollard, Parkinson’s Foundation Vice President and Chief Training and Education Officer. “She achieved so much and will forever inspire us at the Foundation to do more.”

Ruth Hagestuen with 5 friends

Ruth’s dedication to helping people goes back to the beginning on her nursing career when she served as an Air Force nurse in the Vietnam War. Afterwards, she lived and worked for 13 years as a nurse and partner in developing health care programs in Madagascar and Bangladesh. 

In 1987, she accepted the position as nurse coordinator and program manager of the multidisciplinary team in the Parkinson’s clinic at Methodist Hospital, which ultimately expanded to become the Struthers Parkinson’s Center, a Parkinson’s Foundation Center of Excellence, where Ruth worked as Program Director.

“Ruth was tenacious in her willingness and endurance in the pursuit to improve Parkinson’s care,” said Denise Beran, Parkinson’s Foundation Associate Director of Professional Programs. “It has been a privilege to know Ruth as a colleague and as a friend over the past 20 years, and it’s an honor to keep her legacy of professional training alive, continuously improving, seeking the best proven therapies and outcomes to share with health care professionals so they can provide the best possible care.”

Ruth Hagestuen at WPC in 2006

As a speaker and writer, Ruth co-authored the book Health Connect, a Practical Guide to Community Outreach. She also co-authored two publications based on the effectiveness of team care education and facilitated outreach to underserved communities to provide culturally competent, interdisciplinary PD care — nationally and internationally. She was also the Parkinson’s Foundation consultant to the Edmond J Safra National Parkinson’s Wellness Initiative.

Ruth was also active in the International Parkinson’s and Movement Disorders Society, where she served on the Pan-American Section Education Committee.

Kind Words from Our Parkinson’s Community

“Ruth embodied holistic nursing, recognizing the importance of looking beyond the physical symptoms of Parkinson’s. Her work in promoting interprofessional team care as best practice in Parkinson’s forever changed the landscape of care for families living with Parkinson’s.”

- Joan Gardner, RN, BSN, former colleague and life-long friend, former nursing faculty of Team Training

“Ruth was a creative individual with a passion for ensuring that all individuals with Parkinson’s received comprehensive interdisciplinary care. Her life’s work will always be recognized and celebrated within the Parkinson’s community. I am honored to call her my colleague and friend.”

- Rose Wichmann, PT, former colleague and life-long friend, former PT faculty of Team Training

“When I think about Ruth, she is the reminder to follow what you believe in, and in the end, you reach something even better and bigger than you imagined. She was a force within nursing, patient care and education. She advocated not only the education of people with Parkinson’s and their care partners, but also the education and growth of other medical professionals.

- Jenna Iseringhausen, MS, NP, AGPCNP-BC, mentored by Ruth and currently a nurse faculty of Team Training

The Parkinson’s Foundation remembers Ruth’s contribution to the Parkinson’s care field and her direct influence in helping shape Foundation programs that make life better for people with Parkinson’s. Ruth is survived by her wife, Bonnie, her children and grandchildren. 

Learn More

Advancing Research

Mi Historia con EP – Gustavo A. Suárez Zambrano, MD

Gustavo A. Suárez Zambrano

Uniendo el panorama terapéutico

Mi Historia con EP: Gustavo A. Suárez Zambrano, MD, vicepresidente de Asuntos Médicos de Mitsubishi Tanabe Pharma America, Inc.

Mientras crecía en Colombia, su país natal, el Dr. Suárez siempre supo que quería una carrera en la que pudiera ayudar a las personas, aunque no sabía que su camino eventualmente lo llevaría a estudiar la enfermedad de Parkinson (EP) en los Estados Unidos.

El Dr. Suárez trabajó durante varios años como médico general en hospitales de Sudamérica antes de encontrar su verdadera pasión en la neurología. Luego, después de trabajar durante cuatro años como neurólogo general, se dio cuenta de que quería especializarse más aún. Esto hizo que se trasladara a los Estados Unidos, donde consiguió una plaza en la Baylor College of Medicine para estudiar y apoyar la investigación en esclerosis múltiple (EM).

Después de varios años en el ámbito de la EM, el Dr. Suárez decidió asumir un nuevo desafío. Se unió a Mitsubishi Tanabe Pharma America (MTPA) con el objetivo de involucrarse en los trastornos del movimiento y la EP, áreas donde las opciones de tratamiento aún son bastante limitadas. En este momento, muchas personas que viven con la EP experimentan una disminución en la eficacia de los medicamentos orales estándar a medida que avanza su enfermedad, lo que las obliga a tomar múltiples dosis a lo largo del día para tratar de controlar sus síntomas. Como consecuencia, esto puede conducir a la aparición de trastornos motores no controlados, fluctuaciones como movimientos involuntarios o discinesia.2

Hace mucha falta proporcionar opciones terapéuticas que puedan impactar positivamente a los pacientes, especialmente aquellos afectados por fluctuaciones motoras. El trabajo del Dr. Suárez en MTPA se centra en tratar de abordar esta brecha. El doctor comprende la gran necesidad que existe de opciones de tratamiento mínimamente invasivas que puedan ayudar a abordar estos síntomas.

Además de apoyar la investigación y el descubrimiento de nuevas opciones de tratamiento, al Dr. Suárez también le apasiona cerrar la brecha educativa para ayudar a los pacientes. Para esto, ayuda a los cuidadores y a los proveedores de atención médica a comprender nuevos datos y avances en el campo. Las opciones terapéuticas sólo son útiles si quienes viven con la enfermedad y quienes la tratan están informados y son receptivos a ellas.

Después de muchos años en neurología, el Dr. Suárez ahora dedica una gran cantidad de su tiempo a tratar de encontrar nuevas formas de abordar las necesidades y los desafíos insatisfechos de la enfermedad de Parkinson. Entre estos desafíos se incluyen las fluctuaciones motoras, algo con lo que el doctor está comprometido a continuar explorando opciones de tratamiento para las personas que viven con esta enfermedad.

Para obtener más información sobre la EP y comprender las fluctuaciones motoras, visite SpeakParkinsons.com.

Educational Events

Tennessee Parkinson's Symposium

10:00 am to 1:30 pm EST
FREE
Tennessee Parkinson's Symposium

Check-in & Resource Fair start at 9:00 a.m. ET.

Join the Parkinson's Foundation and Erlanger for the Tennessee Parkinson's Symposium. Hear about ongoing research, current treatments, and resources available to help you live your best life with Parkinson's. 

Check-in and Resource Fair start at 9 a.m. Lunch will be served.

There is no charge to attend, but registration is required. This program is open to people with Parkinson's, their families, friends, and the community.

Featured Presenters:

Ellen Valadez, MD
Erlanger Neurology 

Cherry Yu, MD
Vanderbilt Neurology

Trembling Troubadours

Movement Breaks Provided By:

Rock Steady Boxing Chattanooga

YMCA of Chattanooga


A collaboration with Erlanger and the Parkinson's Foundation Tennessee & Kentucky Chapter

erlan

Thank You to Our Program Sponsor:

Supernus Pharmaceuticals logo

COVID SAFETY: The health and safety of our participants, sponsors, volunteers and staff are our top priority. We continue to monitor CDC recommendations and will adhere to state and local COVID guidelines in place on the event day. Adjustments will be made if necessary.

Upcoming Events

Fundraising Events

Flamin’ Ohs - The Parkinson’s Foundation MN Fundraiser

7:00 pm to 10:00 pm CDT
4th Annual The Parkinson's Foundation Minnesota Fundraiser Flamin' Oh's

Twin Cities rock legends Flamin’ Oh's with guest Annie and the Bang Bang return to The Hook & Ladder Theater for an evening of rockin’ fun to support The Parkinson’s Foundation Minnesota and Dakota’s Chapter Fundraiser!

The Oh's soared to the upper echelon of Minnesota bands with their lively shows and exciting brand of straightforward rock & roll. They became one of the earliest bands to make music videos. Chuck Statler (music video pioneer who directed videos for DEVO, Elvis Costello, Nick Lowe and El Vez) directed two videos for the band. The videos aired on a new television network dedicated to music, MTV.

“Hard edged Stones-like rock’n’roll. East Coast street anthems coupled with Midwestern optimism and enthusiasm.” (Minneapolis Star Tribune)

Fronted and founded by fight director, songwriter, and guitarist Annie Enneking, Annie and the Bang Bang are a Minneapolis rock band. Known for their potent and spirited live shows, the band has many moods, mostly of the rock variety. They genre hop from dreamy folkpop to swampy psychedelic grooves to a grunge meets late sixties vibe, crafting musical gems that value energy, animal intelligence, poetry, and mischief. Their collective musical DNA includes REM, Nirvana, PJ Harvey, Joni Mitchell, Led Zeppelin, Neil Young, and Big Star. The band is like a small roving gang of friends, who often develop new material while on writing retreats, tours, and band slumber parties. Adventure is a value of theirs, and they treat every gig as one.

Tickets to the event and donations made at the event are tax deductible. The Parkinson's Foundation utilizes money raised through events like this to fund research to find a cure for the disease, as well as to provide ongoing support to the Parkinson's community.

Upcoming Events

Back to Top